文献速递垂体与肾上腺疾病

侵袭性垂体瘤的治疗策略

Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本文综述了侵袭性垂体腺瘤的治疗方法。此类肿瘤即使经最大程度的手术和放疗仍会生长,可局部侵袭或经血行、脑脊液远处转移。替莫唑胺是唯一证实有效的化疗药物,但客观缓解率至多 50%,中位进展时间短,亟需有效治疗。多种靶向药物仍处于研究阶段。

要点

  • 替莫唑胺是唯一有确切疗效的化疗药物,客观缓解率至多 50%。
  • 再次手术和放疗多用于姑息,很少能根治恶性垂体瘤。
  • 小分子抑制剂、检查点抑制剂等靶向治疗仍处于研究阶段。

核心结论

  • 少部分垂体腺瘤经最大程度手术和放疗仍生长,替莫唑胺是唯一有确切疗效的化疗药物,但疗效有限,亟需新疗法。

研究设计与样本

  • 综述类文章,未报告系统检索范围与样本量。

主要发现

  • 侵袭性垂体瘤有局部侵袭和远处转移(经血行或脑脊液)两种生长模式。
  • 再次手术和放疗可姑息症状,但很少根治。
  • 替莫唑胺客观缓解率至多 50%,中位进展时间短。
  • 小分子抑制剂、检查点抑制剂及其他生物制剂已有活性报道,但仍处于研究阶段。

关键数值与推荐

  • 替莫唑胺客观缓解率至多 50%。

临床怎么用

  • 对标准手术和放疗后仍生长的垂体瘤,可考虑替莫唑胺治疗,靶向药物仅限研究场景。

局限性

  • 综述未报告系统检索策略、样本量及具体疗效数值,靶向治疗证据尚属研究阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A small subset of pituitary adenomas grows despite maximal treatment with standard therapies; namely, surgery and radiotherapy. These aggressive tumors demonstrate 2 patterns of growth: they may be locally aggressive or metastasize distantly, either hematogenously or through the spinal fluid. Further surgery and radiotherapy may be helpful for palliation of symptoms, but they are rarely definitive in the management of these malignant tumors. The only chemotherapy with established activity in the treatment of pituitary tumors is the alkylating agent temozolomide. At most, 50% of patients exhibit an objective response to temozolomide and the median time to progression is short; thus, there remains a significant unmet need for effective treatments within this patient population. Several targeted agents have reported activity in this tumor type-including small molecule inhibitors, checkpoint inhibitors, and other biologics-but remain investigational at this time.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lin AL, Donoghue MTA, Wardlaw SL, et al. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. J Clin Endocrinol Metab. 2020. PMID: 32930787. doi:10.1210/clinem/dgaa649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。